glp-1 in heart failure medications are not just for weight loss — they are the most important drug class of our lifetime. 🫀 A 2025 meta-analysis of 99,599 patients confirmed: ✓ 20% reduction major Early trials of GLP-1 based

However, it is reasonable to assume that the increased risk of nausea and vomiting during anesthesia increases the risk of aspiration in patients taking these drugs

The accepted clinical term is now SADI-S

The brand references "clinically studied botanicals" - but what does peer-reviewed research actually say about the key ingredients

How to Choose the Best Path for You Deciding between GLP-1 agonists and bariatric surgery requires careful thought about your unique circumstances

No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial

Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology